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Allopurinol is a commonly used drug in the treatment of chronic gout or hyperuricaemia associated 
with treatment of diuretic conditions. One of the major problems with the drug is that it is practically 
insoluble in water, which results in poor bioavailability after oral administration. In the present study, 
solid dispersions of allopurinol were prepared by solvent evaporation, kneading method, co-precipitation 
method, co-grinding method and closed melting methods to increase its water solubility. Hydrophilic 
carriers such as polyvinylpyrrolidone, polyethylene glycol 6000 were used in the ratio of 1:1, 1:2 and 1:4 
(drug to carrier ratio). The aqueous solubility of allopurinol was favored by the presence of both polymers. 
These new formulations were characterized in the liquid state by phase solubility studies and in the solid 
state by differential scanning calorimetry, powder X-ray diffraction, UV and Fourier Transform Infrared 
spectroscopy. Solid state characterizations indicated that allopurinol was present as an amorphous material 
and entrapped in polymer matrix. In contrast to the very slow dissolution rate of pure allopurinol, the 
dispersion of the drug in the polymers considerably enhanced the dissolution rate. Solid dispersion prepared 
with polyvinylpyrrolidone showed highest improvement in wettability and dissolution rate of allopurinol. 
Mathematical modeling of in vitro dissolution data indicated the best fitting with Korsemeyer-Peppas model 
and the drug release kinetics primarily as Non-Fickian diffusion. Therefore, the present study showed that 
polyvinylpyrrolidone and polyethylene glycol 6000 have a significant solubilizing effect on allopurinol. 
Uniterms: Allopurinol. Polyethylene glycol 6000. Solid dispersions. Closed melting method. Dissolution 
enhancement.
Alopurinol é fármaco comumente utilizado no tratamento de gota crônica ou hiperuricemia associada com 
o tratamento em condições diuréticas. Um dos maiores problemas com o fármaco é que este é praticamente 
insolúvel em água, o que resulta em baixa biodisponibilidade na administração oral.  No presente estudo, 
dispersões sólidas de alopurinol foram preparadas pela evaporação do solvente, pelos métodos de amassamento, 
de coprecipitação, de comoagem e fusão fechada para aumentar sua solubilidade em água. Transportadores 
hidrofílicos, como polivinilpirrolidona, polietilenoglicol 6000 foram utilizados nas proporções de 1:1. 1:2 
e 1:4 (fármaco: transportador). A solubilidade aquosa do alopurinol foi favorecida pela presença de ambos 
os polímeros. Estas novas formulações forma caracterizadas no estado líquido pelos estudos de solubilidade 
de fase e no estado sólido pela calorimetria diferencial de varredura, difração de Raio-X, espectroscopia de 
UV e de IV com transformada de Fourier.  As caracterizações do estado sólido indicaram que o alopurinol 
estava presente como material amorfo e embebido em matriz polimérica. Ao contrário da velocidade de 
dissolução lenta do alopurinol puro, a dispersão do fármaco nos polímeros aumentou consideravelmente a 
taxa de dissolução. A dispersão sólida preparada com polivinilpirrolidona mostrou as maiores melhorias na 
molhabilidade e taxa de dissolução do alopurinol.  A modelagem matemática dos dados da dissolução in vitro 
indicou o melhor ajuste ao modelo de Korsemeyer-Peppas e a cinética de liberação do fármaco primariamente 
como difusão não-Fickiana. Assim, o presente estudo mostrou que a polivinilpirrolidona e o polietilenoglicol 
6000 têm efeito significativo na solubilização do alopurinol. 
Unitermos: Alopurinol. Polietilenoglicol 6000. Dispersões sólidas. Método de fusão fechada. Aumento 
da dissolução.
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INTRODUCTION
Allopurinol (ALLO), chosen in the current study, is 
a poorly water-soluble drug known to demonstrate limited 
dissolution- or solubility-limited absorption (Ahuja et al., 
2003). Based upon aqueous solubility and various disso-
lution parameters, several methods have been employed 
to improve the solubility of poorly water soluble drugs 
including increasing the particle surface area available 
for dissolution by milling (Habib et al., 1985) improving 
the wettability with surfactants or doped crystals, (Chow, 
1995) decreasing crystallinity by preparing a solid disper-
sion (Flego, 1988), use of inclusion compounds such as 
cyclodextrin derivatives (Pitha, 1985), use of polymorphic 
forms or solvated compounds (Sekiguchi, 1973), and use 
of salt forms.
The enhancement of the bioavailability of poorly 
water-soluble drugs is one of the greatest challenges of 
drug development and several pharmaceutical technolo-
gies have been investigated to this end. Amongst them is 
the solid dispersion of one or more active ingredients in 
inert carriers at solid state prepared by fusion, solvent, 
or solvent-fusion methods (Damian et al., 2000). In solid 
dispersions, the particle size of the drugs was reduced, 
and the wettability and the dispersibility of the drugs were 
enhanced. Consequently, drug dissolution was improved 
markedly (Craig, 2002). Solid dispersion is a promising 
approach to improve the dissolution and bioavailability of 
hydrophobic drugs (Abdul-Fattah et al., 2002).
Hydrophilic polymers have been commonly used 
as carriers for preparing solid dispersions. Among them, 
polyvinylpyrrolidone (PVPk30) has been widely employed 
for its high aqueous solubility, high physiological tolerance, 
and low toxicity. Polyethylene glycols (PEGs) are semi 
crystalline polymers that have been used extensively in solid 
dispersion preparations for their wetting, solubilizing and 
surface active properties (Sethia et al., 2004).
In recent years, interest in incorporating a surface-
active carrier into solid dispersion has increased greatly 
and a high improvement in drug dissolution was reported 
(Serajuddin, 1999; Pathak et al., 2008). This approach has 
been reported to enhance the solubility, dissolution and 
bioavailability of many poorly water soluble drugs using 
various techniques including melting agglomeration and 
melting. The present study was planned to improve the 
aqueous solubility and dissolution rate of ALLO by pre-
paring the solid dispersion with polyethylene glycol 6000 
(PEG 6000) and PVPk30 employing various methods 
such as solvent evaporation (SE), co-precipitation (CP), 
co-grinding (CG), kneading (KN) and the closed melting 
method (CM). The study further aimed to characterize the 
interaction of ALLO with PEG 6000 and PVP K30 in the 
solid state by Fourier Transform Infrared Spectroscopy 
(FTIR), Differential Scanning Calorimetry (DSC), and 
Powder X-Ray Diffraction (PXRD) to check the dissolu-
tion behavior of solid dispersions.
MATERIAL AND METHODS
Material
Allopurinol (ALLO) was kindly supplied by Nico-
las Piramal, (Pitampur, India) and PVPk30 was obtained 
from Oxford Laboratory (Mumbai, India). PEG 6000 
was purchased from Analab Fine Chemicals (Mumbai, 
India). All other chemicals and solvents were of analytical 
reagent grade. Freshly prepared distilled water was used 
throughout the study.
Methods
Phase solubility studies
Solubility measurements were performed in tripli-
cate using the method reported by Higuchi and Connors 
(Higuchi et al., 1965). An excess amount of ALLO was 
added to the aqueous solutions of each carrier containing 
increasing concentrations of the individual carrier (i.e., 0, 
1, 5, and 10 % w/v). The flasks were then maintained at 
25 °C for 7 days with continuous stirring by a magnetic 
stirrer. The saturated solution was sonicated for 20min. and 
then centrifuged; the supernatant were filtered through a 
whatman filter paper no. 1. The filtrate was suitably diluted 
and analyzed spectrophotometrically at λmax 250 nm on 
a Varian carry 100, UV–Vis Spectrophotometer, Australia 
(Ahuja et al., 2007).
Preparation of physical mixture and solid dispersions
· Physical mixtures (PM)
For the sake of comparison, physical mixtures (PM) 
of ALLO were prepared by mixing accurately weighed 
amounts of ALLO with carriers (ratio of drug: carrier was 
1:1, 1:2 and 1:4) in a mortar by simple trituration.
· Solvent evaporation method (SE)
SDs were prepared by dissolving accurately 
weighed amounts of ALLO and PEG 6000 in ethanol. 
After complete dissolution of ALLO and PEG 6000 in 
ethanol the solution was sonicated for 20 minutes, and 
then solvent was evaporated under reduced pressure 
at room temperature in a dessicator. Subsequently, the 
solid mass was ground through sieve no. 40. The sieved 
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ground powders were kept in an oven for 48 hrs at 60 ºC 
(George et al., 2006).
· Co-grinding method (CG)
ALLO was triturated with the minimum quantity of 
ethanol in a glass mortar until dissolved. PEG 6000 was 
then added and the suspension triturated rapidly at room 
temperature until the solvent evaporated. The resulting 
powder was passed through sieve no 40 (Nokhodchi et 
al., 2007).
· Kneading method (KN)
A mixture of ALLO and PEG 6000 was wetted with 
water and kneaded thoroughly for 30 minutes in a glass 
mortar. The paste formed was dried under vacuum for 24 
hrs. Dried powder was passed through sieve no. 40 and 
stored in a dessicator until further evaluation (Modi et 
al., 2006).
· Co-precipitation method (CP)
SDs were prepared by dissolving accurately wei-
ghed amounts of PEG 6000 in water and drug in ethanol. 
After complete dissolution, the aqueous solution of the 
carrier was then poured into the ethanolic solution of the 
drug. The solvents were then heated and evaporated un-
der reduced pressure at room temperature in a dessicator. 
Subsequently, the solid dispersions were passed through 
sieve no. 40 and kept in an oven for 48 hrs. at 60 ºC (Dixit 
et al., 2007).
· Closed Melting method (CM)
One gram of physical mixture of PEG 6000 was 
weighed into glass ampoules (20 ml) which were sealed 
and then heated for 30 minutes in a water bath to prepare 
the solid dispersions. After slow cooling, the ampoules 
caps were opened and the solid dispersions collected. All 
dispersions were pulverized with a pestle and mortar, pas-
sed through sieve no. 40 and dried in an oven for at least 
48 hrs. at 60 ºC (Hasegawa et al., 2005).
Similar procedures were carried out to prepare solid 
dispersions containing PVP K30. Due to the hygroscopic 
nature of PVP K30 sticky lumps are formed by CP and 
CM methods. Therefore, these solid dispersions are not 
applicable for evaluation and characterization studies.
Characterization of solid dispersions
All the formulations were evaluated by phase 
solubility studies and in-vitro dissolution studies. Solid 
dispersions are also characterized by UV, FTIR, DSC and 
PXRD analysis.
· Fourier Transform Infrared spectroscopy (FTIR) studies
FTIR spectra of pure ALLO, PVP, PEG, solid dis-
persions and physical mixture were recorded on a 640 
IR, Varian device, Australia, using the KBr pellet method 
involving trituration of 10 mg of solid dispersions with 
10-20 mg of dry KBr powder and filling of pellets with 
this for scanning at 4000 to 400 cm-1.
· UV-Visible Spectroscopy
UV-Visible Spectroscopy was performed by wei-
ghing solid dispersions accurately and dissolving in dilute 
NaOH solution, sufficiently diluting with distilled water to 
produce a final concentration of 10 µg/ml (Londhe et al., 
1999). These solutions were scanned spectrophotometri-
cally in the UV region at 260 nm on a Varian carry 100, 
UV–vis Spectrophotometer, Australia. 
· Differential Scanning calorimetry (DSC) studies
A differential scanning calorimeter (DSC-823e, 
Mettler Toledo, Switzerland) was used to obtain the DSC 
curves of ALLO, its physical mixtures and solid disper-
sions. About 10mg of sample was weighed in a standard 
open aluminum pan, and scanned from 20-450 °C at a 
heating rate of 10 °C/minute while being purged with dry 
nitrogen (Samy E.M., 2000).
· Powder X-ray diffractometry (PXRD) studies
Powder X-ray diffraction (PXRD) patterns were 
traced employing an X-ray diffractometer (Philips PW 
1729 Netherlands.) for all the samples, using an Ni filter, 
Cu K (α) radiation, a voltage of kV, a current of 20 mA and 
a receiving slit of 0.2 inches. The samples were analyzed 
over a 2θ range of 5° to 60°, with a scan step size of 0.020° 
(2θ) and scan step time of 1 second (Samy E.M., 2000). 
In vitro dissolution studies
Release from the solid dispersions was determined 
in a calibrated 8-station USP XXII apparatus (paddle 
method), TDT-08L Electrolab, Mumbai, India. Samples 
of drug, solid dispersions and physical mixture equivalent 
with 10 mg of drug were packed into thin cloth thimbles 
and then immersed in the dissolution medium consisting 
of 900 ml 0.1 N HCl maintained at 37 ºC. The duration of 
the test and the rate of paddle stirring were 90 min and 75 
rpm, respectively. At a time intervals of (5, 10, 15, 20, 30, 
45, 60 and 90 minutes), 5 ml samples were withdrawn, 
and replaced with 5 ml of fresh dissolution medium. The 
samples were filtered through a whatman filter paper No. 
1 and analyzed spectrophotometrically at 250 nm on a 
Varian carry 100, UV–vis Spectrophotometer, Australia. 
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Cumulative percentages of the drug dissolved from the 
preparations were calculated (Pignatello et al., 2002; 
Mahaparale et al., 2006). 
Data analysis
· Phase-solubility studies
The values of apparent stability constant, Ks, betwe-
en each drug-carrier combination were computed from the 
phase-solubility profiles, as described below:
Ks = Slope / Intercept (1- slope) 
The values of Gibbs free energy of transfer, ∆Gotr of 
ALLO from aqueous solution of the carriers were calcu-
lated according to the following relationship
∆Gotr = - 2.303RT.log So/Ss
Where So and Ss are the molar solubilities of ALLO 
in 1 % w/v aqueous solution of the carrier, respectively.
In vitro drug release data was fitted to four popular 
models of data treatment for the formulations as follows: 
1) Zero order: F = k X t 
2) First order: ln F = k X t 
3) Higuchi’s model: F= k√ t
4) Korsmeyer and Peppas model: F= ktn
Where F is the fraction of drug release, k is the relea-
se constant, t is the time and n is the diffusional coefficient. 
The value of n is related to the geometrical shape of the 
delivery system and determines the release mechanism 
from various polymeric drug deliveries.
RESULTS AND DISCUSSION
Phase solubility studies
The current study showed that PVPK30 and PEG 
6000 have a significant solubilizing effect on ALLO. 
Figure 1 shows the phase-solubility curve of ALLO in 
the presence of PVPK30 and PEG 6000. The solubility of 
ALLO in water at R.T. (25 °C) is 137 µg/mL; therefore, 
ALLO can be considered a water-insoluble drug. From 
this curve, it can be seen that the apparent solubility of 
ALLO increased with greater carrier concentrations. Both 
carriers show an AL type of linear graph with increasing 
concentration of carriers.
The obtained values of Gibbs free energy transfer 
(∆Gotr) (Table I) for apparent stability constants (Ks) were 
43.46 and 130.38, for slope 3.78 ×10-4 and 1.16×10-3 with 
R2 values 0.9874 and 0.9823, for PEG 6000 and PVPk30, 
respectively. Negative ∆Gotr values indicate favorable 
conditions. These values also indicated that the extent 
of improvement in solubility was greater with PVP K30 
compared with PEG 6000. The solubility enhancement of 
ALLO obtained with various carriers in water followed the 
rank order of PVP K30> PEG 6000.
 
Characterization of solid dispersion
UV- Visible Spectroscopy studies
UV absorption spectra of ALLO and its solid dis-
persions were determined in 0.1 M NaOH by scanning 
the sample solutions in the range 240 nm to 300nm at a 
1 cm path length. ALLO showed maximum absorption 
(λmax) at 260 nm. Figure 2 shows UV Spectra of allopu-
rinol solid dispersions with PVP K30. The solutions of 
physical mixture and solid dispersions showed absorbance 
at the same λmax i.e. 260 nm but all formulations showed 
slight difference in absorbance compared to allopurinol. 
The decrease in absorbance showed by all solid disper-
TABLE I - Phase solubility parameters of Allopurinol at 25 ºC
Sr. 
No.
Polymer concentration
(%w/v)
Gibb’s free energy of transfer 
ΔGtr
0 (joules/mol)
PEG 6000 PVP K30
1 1 – 2.7 – 4.2
2 5 – 5.2 – 7.0
3 10 – 7.6 – 8.5
FIGURE 1 - Solubility of Allopurinol (g/100ml) in aqueous 
solutions of (A) PEG 6000 and (B) PVP K30 in water at 25ºC
Physicochemical characterization and solubility enhancement studies of allopurinol solid dispersions 517
sions (except KN2-K30 and CG4-K30 that exhibited 
increased absorbance) was due to method variation and 
considered practical errors such as formation of sticky 
lumps. This indicates there is no significant evidence of 
chemical interaction between ALLO and PVP K30. The 
shift in wavelength might be due to the complete incorpo-
ration of drug into the carrier. 
Figure 3 shows the UV spectra of ALLO and its solid 
dispersions with PEG 6000. The UV absorption spectra of 
ALLO and its solid dispersions in PEG 6000 were obtained 
at the same scanning rate as PVPk30. All the dispersions 
exhibited decreased absorbance but the spectra of all solid 
dispersions were shifted to the higher wavelength due to 
the high polarity of the solvent i.e. NaOH as shown in Fi-
gure 3. This is considered significant evidence of chemical 
interaction between ALLO and PEG 6000.
Fourier Transform Infrared spectroscopy (FTIR) studies
The FTIR spectrum of ALLO exhibited character-
istic signals at 790, 811, 915, 1159, and 1232 cm−1 (CH 
in plane deformation), 1590 cm−1 (ring vibration), 1700 
and 1763 cm−1 (CO stretching vibration of the keto form 
of the 4-hydroxytautomer), 3060 cm−1 (CH stretching 
vibrations of pyrimidine ring), 3400 cm−1 (NH stretching 
band), respectively. 
Important vibrations detected in the spectrum of 
PEG 6000 are C–H stretching at 2890 cm−1 and C–O 
(ether) stretching at 1125 cm−1.
The spectra of the physical mixture (PM2-P60) 
can simply be regarded as the superimposition of those 
of ALLO and PEG 6000 (Figure 4). No difference was 
observed in the position of the absorption bands of ALLO 
and PEG 6000. The characteristic peaks of PEG 6000 were 
present at almost the same positions, while the absence of 
shifts in the wave numbers of the FTIR peaks of the solid 
dispersions vis-a-vis the PM indicate the lack of significant 
interaction between the drug and the carrier in the solid 
dispersions. Thus, these results confirm the absence of any 
well-defined interaction between ALLO and PEG 6000.
Figure 5 displays the FTIR spectra of pure ALLO, 
PVP K30, PM and solid dispersions prepared by KN, 
CG and SE methods. PVP K30 exhibited peaks of C-H 
stretch vibration (2955 cm−1) and –C=O stretch vibration 
(1663 cm−1). The solid dispersions of all ratios (1:1, 1:2 
and 1:4) showed that the principle peaks of ALLO i.e. 1700 
and 1763 cm−1 (CO stretching vibration of the keto form of 
the 4-hydroxytautomer), 3060 cm−1 (CH stretching vibra-
tions of pyrimidine ring), 3400 cm−1 (NH stretching band) 
were smoothened, weakened and splits. These observa-
tions indicated intermolecular hydrogen bonding via N-H, 
C-H and C-O groups of ALLO and –C=O stretch vibration 
of PVP. This result confirms significant drug-polymer 
interaction (Shah et al., 2007; Gurusamy et al., 2006). 
FIGURE 2 - UV Spectra of Allopurinol SDs with PVP k30
FIGURE 3 - UV Spectra of Allopurinol SDs with PEG 6000
FIGURE 4 - FT-IR spectra of Allopurinol, physical mixture and 
its solid dispersions in PEG 6000 by CG and KN methods.
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Differential Scanning Calorimetry (DSC) studies
The DSC curve of ALLO and PEG 6000 showed 
sharp endothermic peaks at 379.5 ºC and 62.7 ºC respecti-
vely, due to fusion (Figure 6) corresponding to its melting 
point. The DSC curve of (CM4-P60) solid dispersion 
prepared by CM showed that the sharp endothermic peak 
was equivalent to the addition curves of PEG 6000 and 
crystalline drug (ALLO). It indicates lower crystallinity 
because of less cross-linking between ALLO and PEG 
6000. The physical mixture and solid dispersion prepared 
by the solvent evaporation method (SE2-P60) showed 
an ALLO and PEG 6000 derived endothermic peak with 
lower intensity than pure ALLO. The possibility of drug 
dissolution in the melting carrier has been previously 
reported (Okonogi et al., 2006) Therefore, DSC results 
suggested that crystalline ALLO in the ALLO-PEG solid 
dispersions were dissolved in melting PEG during the 
DSC scan.
Figure 7 shows the DSC curves of ALLO, PVPk30 
and solid dispersions (KN4-K30, SE1-K30 and CG2-
K30). ALLO and PVPk30 show endothermic peaks at 
379.5 ºC and 80ºC, respectively. The sharp endothermic 
peaks corresponding to melting of ALLO becomes bro-
ad in DSC thermograms of solid dispersions. However, 
solid dispersion (KN4-K30) showed the ALLO-derived 
endothermic peaks with greater intensity than pure ALLO. 
This might be due to the amorphous form of ALLO in the 
solid dispersion or dissolution of crystalline ALLO into 
the molten carrier.
The shift and breadth of the endothermic peaks pro-
bably results from the partial reduction in crystallinity of 
ALLO, which can be confirmed in PXRD studies.
Powder X-ray diffractometry (PXRD) studies
The diffraction peaks of ALLO, carriers, PM and 
solid dispersions were given for comparative purposes. 
The PXRD patterns of ALLO, PEG 6000 and its binary 
systems are compared in Figure 8. The diffraction pat-
tern of pure drug reveals its highly crystalline nature, as 
indicated by the numerous distinctive peaks. The PEG 
6000 alone exhibited two high intensity peaks at 19º and 
FIGURE 5 - FT-IR spectra of Allopurinol, physical mixture and 
its solid dispersions in PVP K30 CG, by KN and SE methods.
FIGURE 6 - DSC Thermographs of SDs with PEG 6000; a) 
ALLO, b) PEG 6000, c) PM-P60, d) SE2-P60, e) CM4-P60.
FIGURE 7 - DSC Thermographs of SDs with PVP K30; a) 
ALLO, b) PVP K30, c) KN4-K30, d) SE1-K30, e) CG2-K30.
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23º. The lack of the numerous distinctive peaks of the 
drug in the PM and solid dispersions demonstrated that 
a high concentration of the drug was dissolved in solid 
state carrier matrix in an amorphous state. This suggests 
the ALLO present in the solid dispersion is mostly in 
an amorphous state with only few partially crystallized 
drug molecules. 
PXRD patterns of ALLO, PVP K30, PM and solid 
dispersions are shown in Figure 9. In the X-ray diffrac-
tograms of ALLO, sharp peaks at a diffraction angle (2θ) 
of 7.01º, 9.66º, 11.5 º, 19.21º, 20.08 º and 35.07 º indicate 
the presence of  crystalline drug, while PM and solid dis-
persion show a single sharp peak at 24.88 º. These data 
revealed that the diffraction patterns of all the samples of 
solid dispersions have peaks due to PVP but the typical 
drug crystalline peaks are totally absent, thus indicating 
the crystalline nature of ALLO converted to an amorphous 
state (Shah et al., 2007; Gurusamy et al., 2006). 
In vitro dissolution study
The dissolution rate of pure ALLO was very poor 
and during a 90-minute period, a maximum of around 
54.53 % of drug was released. The reason for the poor 
dissolution of pure drug could be poor wettability and/or 
agglomeration. 
Figure 10, Figure 11 and Figure 12 show the plot of 
cumulative per cent drug released as a function of time for 
different formulations. In vitro release studies revealed 
that there was a marked increase in the dissolution rate of 
ALLO, in the range of 65.8 to 99.8 %, from all Physical 
mixtures and solid dispersions compared to pure ALLO 
except for CP2-P60, KN1-P60 and CM1-P60 (Figure 10, 
Figure 11 and Figure 12). This might be secondary to 
the improper distribution of drug in these formulations 
due to the method variation. Among the different ratios 
prepared, the enhancement of dissolution rate was found 
to be 1:4>1:2>1:1.
The results revealed that the solid dispersions pro-
duced by co-grinding and solvent evaporation techniques 
have higher dissolution rates of pure ALLO at all ratios 
compared with the samples produced by KN, CP and CM 
methods. This could be due to molecular dispersion of 
drug in the samples and drug amorphization. Hence, the 
present study showed the SE and CG techniques are more 
efficient than KN, CP and CM techniques for increasing 
the dissolution of ALLO by using PEG 6000 as a hydro-
philic carrier.
Figures 13 and 14 show comparative in vitro release 
profiles of pure ALLO, physical mixture and various solid 
dispersions of ALLO with PVP K30, prepared by the KN, 
CG and SE methods. In vitro release studies revealed a 
marked increase in dissolution rate of ALLO from all 
FIGURE 8 - PXRD pattern of SDs with PEG 6000; a) ALLO, b) 
PEG 6000, c) PM4-P60, d) CM4-P60, e) CG2-P60.
FIGURE 9 - PXRD pattern of SDs with PVP K30; a) ALLO, b) 
PVP K30, c) PM-K30, d) SE1-K30, e) KN4-K30.
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solid dispersions when compared to pure ALLO. Based 
on the release profile, 1:2 ratios of KN and CG methods 
showed consistency in the release pattern of drug after 20 
minutes without increasing the further release of drug. 
This stoppage in the dissolution rate may be due to the 
increase in the viscosity of coating material. The increase 
in dissolution rate may be the result of  solubility enhan-
cement by improving the wettability of drug particles due 
to its surfactant property. 
Kinetic treatment of dissolution data
The coefficient of determination was considered the 
main parameter for interpreting the results. The n values 
of all formulations are as reported in Table II and III. All 
formulations of solid dispersions were not fitting to a 
specific model (Patel et al., 2008). 
Only two formulations, i.e. KN4-P60 and CG1-P60, 
followed first order kinetics with R2 values of 0.9708 and 
0.9838, respectively. Formulations KN1-P60, CM1-P60, 
CP1-P60, CP2-P60, and SE1-P60 follow Higuchi kinetics 
with R2 values 0.9874, 0.9954, 0.9848, 0.9897 and 0.9938, 
respectively.
The release kinetic analyses of all formulations are 
as shown in Table 2. For formulations containing PEG 
6000, KN1-P60, CM1-P60, CM2-P60 and SE1-P60, n 
values were 1.0495, 1.036, 1.0372 and 1.2869, respec-
FIGURE 10 - In vitro Drug release profile of ALLO-PEG 6000 
binary systems by Co-precipitation method.
FIGURE 11 - In vitro Drug release profile of ALLO-PEG 6000 
binary systems by kneading and Co-grinding methods.
FIGURE 12 - In vitro Drug release profile of ALLO-PEG 6000 
binary systems by Closed melting and Solvent evaporation 
methods.
FIGURE 13 - In vitro Dissolution profile of ALLO-PVP K30 
binary systems by kneading and Co-grinding methods.
FIGURE 14 - In vitro Drug release profile of ALLO-PEG 6000 
binary systems by Closed melting and Solvent evaporation 
methods.
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tively, indicating that the release mechanism from these 
systems was super case II transport. Formulations KN2-
P60, KN4-G50, CP2-P60, SE2-P60, CG1-P60, CG2-P60 
and CG4-P60, had n values ranging from 0.4817 to 0.7282 
indicating that the release mechanism from these systems 
was the anomalous type (Non Fickian transport), which 
refers to a combination of both diffusion and erosion 
controlled-drug release.
Kinetic treatment for PVP K30 solid dispersions
Only one formulation i.e. SE2-K30, followed first 
order kinetics with an R2 value of 0.9827. Formulations 
KN1-K30 and KN4-30 followed Higuchi kinetics with 
R2 values of 0.983 and 0.988, respectively. The release 
kinetic analyses of all formulations are as shown in Table 
3. All formulations showed n values ranging from 0.5207 
to 0.7361 except KN2-K30 and CG2-K30, whose n va-
lues were less than 0.5 and hence their release mechanism 
is not understood. Given these n values, it is concluded 
that the release mechanism from these systems was the 
anomalous type (Non Fickian transport), which refers to 
a combination of both diffusion and erosion controlled-
drug release.
CONCLUSION
Finally, based on the above study, it was concluded 
that the solid dispersion technique was shown to be a 
successful approach for improving the dissolution rate 
of allopurinol. The nature and amount of the carrier used 
played an important role in the enhancement of the disso-
lution rate. The increased solubility and dissolution rate 
of ALLO provided the rapid onset of action.
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TABLE II - Kinetic treatment of dissolution data of allopurinol Solid Dispersions in PEG 6000
Formulation
Code
Coefficient of determination(r2)
Zero order First order
Higuchi 
square
Korsemeyer 
Peppas
Korsemeyer n 
(release exponent)
ALLO 0.9251 0.9197 0.8711 0.9262 0.5134
PM4-P60 0.9809 0.9557 0.9726 0.9821 0.69
KN1-P60 0.9699 0.9222 0.9874 0.9815 1.0495
KN2-P60 0.9879 0.9184 0.978 0.9527 0.7282
KN4-P60 0.9533 0.9708 0.8855 0.9209 0.6052
CM1-P60 0.9721 0.9527 0.9954 0.9804 1.036
CM2-P60 0.9455 0.9249 0.878 0.8901 1.0372
CM4-P60 0.8822 0.5627 0.9201 0.9285 0.2174
CP1-P60 0.9937 0.9731 0.9848 0.9967 0.1648
CP2-P60 0.9422 0.9051 0.9897 0.9785 0.7042
CP4-P60 0.8929 0.5736 0.9278 0.9219 0.2272
SE1-P60 0.9609 0.8303 0.9938 0.9531 1.2869
SE2-P60 0.9771 0.9566 0.9279 0.9552 0.6311
SE4-P60 0.6414 0.6498 0.521 0.6878 0.093
CG1-P60 0.9639 0.9838 0.9021 0.9037 0.5974
CG2-P60 0.9811 0.7955 0.9717 0.9684 0.4817
CG4-P60 0.9212 0.9141 0.8369 0.8497 0.6573
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